Costello Syndrome Clinical Trials

Find Costello Syndrome Clinical Trials Near You

An Open-Label Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Pediatric Patients With Familial Chylomicronemia Syndrome (FCS)

Status: Recruiting
Location: See all (4) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

The primary purpose of the study is to evaluate the efficacy of olezarsen administered by subcutaneous injection to pediatric participants with FCS.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 2
Maximum Age: 17
Healthy Volunteers: f
View:

• Parental or legally authorized representative consent must be obtained, and the participants must provide age-appropriate or cognition-appropriate assent, as determined by the Investigator. The parent or legal guardian must be able to understand and comply with the study visit schedule and all other study procedures.

• Must be able to comply with all study procedures.

• Age 12 to less than 18 years at the time of informed consent/assent (Cohort 1); age 2 to less than 12 years at time of informed consent/assent (Cohort 2).

• Willing to fast for at least 10 hours before visits requiring fasted blood sampling.

• A diagnosis of Familial Chylomicronemia Syndrome (type 1 Hyperlipoproteinemia) by documentation of confirmed homozygote, compound heterozygote or double heterozygote for loss-of-function mutations in type 1-causing genes.

• Fasting TGs ≥880 mg/dL at screening. If fasting TG is \< 880 mg/dL, up to two additional tests may be performed during the screening period with any single test used to qualify.

Locations
United States
Alabama
University of Alabama
RECRUITING
Birmingham
California
UCSF Benioff Children's Hospital
RECRUITING
San Francisco
Texas
University of Texas Southwestern Medical Center
RECRUITING
Dallas
Cook Children's Medical Center
RECRUITING
Fort Worth
Contact Information
Primary
Ionis Pharmaceuticals, Inc.
IonisOlezarsenPediatric@clinicaltrialmedia.com
(844) 200-6410
Time Frame
Start Date: 2026-07-31
Estimated Completion Date: 2031-08
Participants
Target number of participants: 12
Treatments
Experimental: Cohort 1
Participants aged 12 to \<18 years will receive multiple doses of olezarsen, at a dose level that depends on body weight, once every month by subcutaneous injection for up to 1 year. All participants may continue to the optional 1-year long-term extension period with the last dose received being after 2 years of treatment.
Experimental: Cohort 2
Participants aged 2 to \<12 years will receive multiple doses of olezarsen, at a dose level based on information obtained from Cohort 1, once every month by subcutaneous injection for up to 1 year. All participants may continue to the optional 1-year long-term extension period with the last dose received being after 2 years of treatment.
Sponsors
Leads: Ionis Pharmaceuticals, Inc.

This content was sourced from clinicaltrials.gov